SCHEMBL5359429

SCHEMBL5359429

Clc1nc2ccccc2nc1Oc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.54
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 4/20 0.49
HTT P42858 3/20 0.49
MAPT P10636 2/20 0.49
HPGD P15428 2/20 0.49
LMNA P02545 1/20 0.49
HRH4 Q9H3N8 3/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
KMT2A Q03164 2/20 0.47
GLA P06280 1/20 0.47
PKM P14618 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
RAB9A P51151 1/20 0.45
MEN1 O00255 1/20 0.44
PIN1 Q13526 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10706728 0.85 LTA4H (0.47) TDP1KDM4EALDH1A1HTTMAPT
SCHEMBL20540182 0.85 HTT (0.57) KDM4EALDH1A1HTTMAPTHPGD
SCHEMBL4309134 0.78 RAB9A (0.53) TDP1KDM4EALDH1A1HTTMAPT
SCHEMBL18796358 0.77 ALDH1A1 (0.56) TDP1KDM4EALDH1A1HTTMAPT
SCHEMBL27906795 0.77 HRH4 (0.47) KDM4EALDH1A1HTTMAPTHPGD
SCHEMBL2178510 0.75 TDP1 (0.58) TDP1KDM4EALDH1A1MAPTLMNA
SCHEMBL10750391 0.74 HRH4 (0.48) TDP1KDM4EALDH1A1HTTMAPT
SCHEMBL11089516 0.74 PIN1 (0.53) TDP1KDM4EALDH1A1HTTMAPT
SCHEMBL18796101 0.74 LCK (0.51) TDP1KDM4EALDH1A1HTTLMNA
SCHEMBL15147752 0.73 LMNA (0.64) TDP1KDM4EALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291645-B2 Phenylalanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. (US) 2007-11-06 US disclosed
US-7015216-B2 Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. (US) 2006-03-21 US disclosed
US-20040127486-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. 2004-07-01 US disclosed
US-6689781-B2 TREATING AN INFLAMMATORY CONDITION IN A MAMMALIAN PATIENT WHICH CONDITION IS MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. 2004-02-10 US disclosed
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-07-04 US disclosed
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-05-09 US disclosed
US-20020028812-A1 Phenylalanine derivatives CELLTECH CHIROSCIENCE LIMITED (GB) 2002-03-07 US disclosed
US-6348463-B1 Phenylalanine derivatives CELLTECH THERAPEUTICS LIMITED (GB) 2002-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ITGB4, ITGA4, ITGB3 TDP1 2901/4885KDM4E 469/4885ALDH1A1 1200/4885
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors ITGAL, ITGB4, ITGA4 TDP1 4182/4885KDM4E 2953/4885ALDH1A1 593/4885
US-20020028812-A1 Phenylalanine derivatives PAH, FPR1, VCAM1 TDP1 1442/4885KDM4E 1423/4885ALDH1A1 330/4885
US-20040127486-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ITGB4, ITGA4, ITGB3 TDP1 2901/4885KDM4E 469/4885ALDH1A1 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.